0318 Aktis ECP
BioCentury & Getty Images

Emerging Company Profile

Through Aktis, MPM bets on radiotherapy for solid tumors

Emerging Company Profile: Aktis raises $72M A round to develop alpha-emitting radiotherapies with differentiated PK

Aktis Oncology raises a $72 million A round to develop α-emitting radiotherapies with differentiated PK.

Mar 18, 2021 | 11:43 PM GMT

Aktis believes the pharmacology of its solid tumor-targeting

Read the full 608 word article

How to gain access

Continue reading with a
two-week free trial.